SCHEMBL4434685

SCHEMBL4434685

Cc1ccc(C(C)O)cc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
TSHR P16473 2/20 0.53
CYP3A4 P08684 1/20 0.53
RECQL P46063 1/20 0.53
GRM8 O00222 1/20 0.49
GRM6 O15303 1/20 0.49
GRM4 Q14833 1/20 0.49
EPAS1 Q99814 1/20 0.48
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
HSD17B10 Q99714 1/20 0.46
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2883857 0.86 TSHR (0.53) ALDH1A1TSHRCYP3A4RECQLEPAS1
SCHEMBL26352809 0.86 TSHR (0.53) ALDH1A1TSHRCYP3A4RECQLEPAS1
SCHEMBL26352787 0.86 TSHR (0.53) ALDH1A1TSHRCYP3A4RECQLEPAS1
SCHEMBL2436243 0.85 TSHR (0.56) ALDH1A1TSHRCYP3A4RECQLGRM8
SCHEMBL15927423 0.84 TSHR (0.55) ALDH1A1TSHRCYP3A4RECQLGRM8
SCHEMBL15854544 0.83 APP (0.57) ALDH1A1TSHRCYP3A4RECQLCES2
SCHEMBL27859132 0.83 TSHR (0.54) ALDH1A1TSHRCYP3A4RECQLGRM8
SCHEMBL2756243 0.83 GRM8 (0.53) ALDH1A1TSHRCYP3A4RECQLGRM8
SCHEMBL16313203 0.82 TSHR (0.53) ALDH1A1TSHRCYP3A4RECQLGRM8
SCHEMBL16959578 0.82 TSHR (0.53) ALDH1A1TSHRCYP3A4RECQLGRM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101668749-A Novel pyrimidine derivatives 698 ASTRAZENECA AB 2010-03-10 CN disclosed
EP-2132184-A1 NOVEL PYRIMIDINE DERIVATIVES 698 AstraZeneca AB (SE) 2009-12-16 EP disclosed
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-10-02 US disclosed
WO-2008104754-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-09-04 WO disclosed
CN-1156451-C Betz 2-adrenoceptor agonists ��˹��ŵ�� 2004-07-07 CN disclosed
CN-1353692-A Betz 2-adrenoceptor agonists NOVARTIS AG (CH) 2002-06-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 EPHB4, EPHB1, NME2 ALDH1A1 1143/4885TSHR 2708/4885CYP3A4 1606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.